THE COST-EFFECTIVENESS OF DEPRESSION SCREENING FOR THE GENERAL ADULT POPULATION

Melike Yildirim[1,2], PhD, Bradley N Gaynes[3,4], MD, MPH, Pinar Keskinocak[1,5], PhD, Brian W Pence[4], PhD, Julie Swann[6], PhD

[1] *School of Industrial and Systems Engineering and Center for Health and Humanitarian Systems, Georgia Institute of Technology, Atlanta, GA, USA.*
[2] *Institute for Technology Assessment and Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.*
[3] *Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.*
[4] *Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.*
[5] *Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.*
[6] *Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC, USA.*

Corresponding Author: Julie Swann, Ph.D., Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, North Carolina, USA, 111 Lampe Drive CB7906, Raleigh, NC 27695. Tel.: 919-515-6423; e☐mail: jlswann@ncsu.edu

Conflicts of Interest: None reported.

ABSTRACT

Background.

Depression is a treatable disease, and untreated depression can lead to serious health complications and decrease the quality of life. Therefore, prevention, early identification, and treatment efforts are essential. Screening has an essential role in preventive medicine in the general population. Ideally, screening tools detect patients early enough to manage the disease and reduce symptoms. We aimed to determine the cost-effectiveness of routine screening schedules.

Methods.

We used a discrete-time nonstationary Markov model to simulate the progression of depression. We used Monte Carlo techniques to simulate the stochastic model for 20 years or during the lifetime of individuals. Baseline and screening scenario models with screening frequencies of annual, 2-year, and 5-year strategies were compared based on incremental cost-effectiveness ratios (ICER). Monte Carlo (MC) simulation and one-way sensitivity analysis were conducted to manage uncertainties.

Results.

In the general population, all screening strategies were cost-effective compared to the baseline. However, male and female populations differed based on cost over quality-adjusted life years (QALY). Females had lower ICERs, and annual screening had the highest ICER for females, with 11,134$/QALY gained. In contrast, males had around three times higher ICER, with annual screening costs of 34,065$/QALY gained.

Limitations. We assumed that the screening frequency was not changing at any time during the screening scenario. In our calculations, false-positive cases were not taking into account.

Conclusions.

Considering the high lifetime prevalence and recurrence rates of depression, detection and prevention efforts can be one critical cornerstone to support required care. Our analysis combined the expected benefits and costs of screening and assessed the effectiveness of screening scenarios. We conclude that routine screening is cost-effective for all age groups of females and young, middle-aged males.

Key words: Cost-effectiveness, major depression, minor depression, routine screening, incremental cost-effectiveness ratio (ICER)

INTRODUCTION

Depression is one of the most common mental health conditions and a leading cause of disability that results in substantial impairment (Goodwin, 2006). Both major depression and minor depression present with either depressed mood or loss of interest or pleasure in usual activities along with other symptoms, and the signs are present for two weeks or longer. Minor depression, with a few mild symptoms, can be resolved without treatment, but it may evolve into major depression. Major depression with moderate or severe symptoms significantly impacts life quality and may require treatment from a mental health specialist. However, most depression cases are treated in general medical settings in practice (Kessler et al., 2010).

On average, 22.9% of females and 15.1% of males experience at least one episode of major depression in their lifetime, and 43.3% of patients are not receiving any treatment (Kessler et al., 2010). Between 1999 and 2019, suicide rates, whether with an underlying diagnosis of depression or not, increased by 33% in the overall population (Center for Disease Control and Prevention, 2020). A 50% increase in suicide rates was observed among women from 2000 to 2016 (Center for Disease Control and Prevention, 2020).

Depression co-occurs highly with other physical illnesses, which causes health and economic burdens to individuals and society. It is estimated that depression cost $210 billion in 2010, including direct and indirect costs (e.g., loss of productivity) (Greenberg et al., 2015). Considering high prevalence and low detection rates, improved management of disease may reduce health spending and improve patients' quality and quantity of life. Due to the high cost and the negative impacts on patients' overall health, improved detection efforts may be adopted by policymakers and healthcare agencies.

Routine depression screening can be used to improve the recognition of depressive episodes. In some health systems, screening is commonly used; in other settings, implementation is limited (O'Connor et al., 2016). Therefore, in current clinical practice, screening measures are variable. According to the National Ambulatory Medical Care Survey (NAMCS) in the United States, only 2.29 percent of primary care visit patients were screened for depression in 2010 (National Center for Health Statistics, 2018). Whereas, in postpartum populations, screening is implemented on a large scale (79%) (Sleath et al., 2007). The U.S. Preventive Services Task Force (USPSTF) suggests screening of patients with a system that accurately diagnoses, treats,

and follows up with the patients. Still, the benefit of screening, optimal screening interval, and
timing is unknown (O'Connor et al., 2016; U.S. Preventive Services Task Force, 2016). Studies
in literature questioned the USPSTF recommendations (Thombs et al., 2012), and most of them
are limited to show the cost-effectiveness of routine depression screening (Valenstein et al.,
2001).

The frequency of screening of the general population in different health settings is
uncertain. Therefore, evaluation of medical benefits (e.g., decrease the recurrence, relapses,
improve treatment success and increase the symptom-free days) and costs of routine depression
screening strategies remain essential. In this study, we aimed to determine the cost-effectiveness
of routine screening schedules. We assessed the various routine screening frequencies for the
general population and specific age groups of females and males.

METHODS

Model Structure

A natural history model was introduced where probabilities were assigned to each health
state based on patient characteristics such as age, gender, and history of depression. We used a
discrete-time nonstationary Markov chain model, a probability distribution that changes as health
state, history of depression changes, and time progress. The model consists of ten health states:
healthy, major depression without treatment, major depression with treatment, partial remission,
full remission from major depression, minor depression without treatment, minor depression
with treatment, full remission from minor depression, suicide, and death from other causes
(Figure 1). States were similar to Valenstein et al.'s and others' (Ross et al., 2019; Valenstein et
al., 2001) model.

We classified the existence of 2 to 4 depressive symptoms (e.g., feelings of
worthlessness, loss of interest, sleep disturbance or sleeping too much, reduced appetite, fatigue)
as minor depression (Fils et al., 2010). We considered patients in partial remission of current
major depression when they have experienced the residual symptoms of the most recent episode
of depression (National Institute for Health and Clinical Excellence: Guidance, 2010). Healthy
state included individuals who were never depressed (minor or major).

We considered the following scenarii i) baseline (no screening), ii) annual screening, iii)
screening every 2 years, and iv) screening every 5 years. We evaluated the case of screening for

the overall population, starting at the age of 18. For screening scenarii, we assumed that the screening tool could increase the probability of patients to diagnosis. We used Monte Carlo techniques to simulate the stochastic model for 20 years or during the lifetime of individuals. Since depression treatment generates long-term benefits, we modeled for a 20-year time horizon, similar to others in the literature (Mark T. Linthicum et al., 2016; Valenstein et al., 2001).

We ran each scenario for 1000 replications. At the entry, patients were assigned their initial states based on prevalence, and they transitioned between states at the end of each year. The initial population of 100,000 individuals was introduced to the system based on U.S. age distribution (Howden and Meyer, 2010) and a constant number of people preserved in the system. In each time unit, the number of 18-year-old individuals entering the system was equal to the number of people leaving the system from states of suicide or death from other causes. We used R (version 3.6.2) in our analysis.

Model Parameters

We derived the model parameters from published data. Time-sensitive transition probabilities were used, where the mortality probabilities were increased by age. We used annual transitions that depend on patient histories, such as the number of previous episodes, treatment status, time spent without treatment, and demographics (age, gender) if applicable. Table 1 shows the parameters that were used in the baseline model and their sources.

When there was no consensus in the literature for a parameter value, we chose conservative estimates. For example, for the incidence of major depression, we used the lower bound of rates reported in the ECA study (Eaton et al., 2007). Consequently, our results were not biased towards screening.

Prevalence and Incidence

The ECA study's incidence rates yield a 50% lifetime prevalence of major depression (Eaton et al., 1997), which is higher than reported in the literature. There are arguments around the potential discordance between incidence and lifetime prevalence rates of major depression (Takayanagi et al., 2014).

To be consistent with the reported incidence rates from national surveys, we used a lower bound of incidence (Eaton et al., 2007). We integrated the matching lifetime prevalence using a

recall bias of 31.9% for females and 16.3% for males, and a 12-month prevalence recall bias of

25.5% for females and 9% for males, which were obtained from the literature (Yildirim et al.,

2021).

Detection and treatment

We had a detection rate of 45% for major depression and 30% for minor depression in the

baseline model (Valenstein et al., 2001). 43 to 60% (Kessler et al., 2010) of patients who

initiated the treatment from major depression depend on the age of onset, whereas 20%

(Valenstein et al., 2001) of cases with minor depression received treatment. The multiplication of

these two probabilities ((detection rate)*(initiation of treatment)) represented the transitions from

without treatment to with treatment state.

Treatment increased the full remission rate by 35% (0.37 without treatment vs. 0.50 with

treatment) for major depression and 29% (0.55 without treatment vs. 0.71 with treatment) for

minor depression (Table 1).

Early treatment efforts had an impact on the outcome of antidepressant treatment (Kraus et

al., 2019). Duration of untreated illness (DUI) longer than 6 months decreased the effect of

antidepressant treatment. Patients who spent more than 12 months without treatment status have

reduced remission likelihood by one-third (Bukh et al., 2013).

Transition to remission state depended on the healthcare provider and the type of treatment.

We assumed that 31% of major depression and 25% of minor depression cases were treated by a

specialist (Valenstein et al., 2001). Patients were treated with medications in primary care

(Valenstein et al., 2001). Whereas psychotherapy, medication, or a combination of these two was

used during the treatment of a specialist.

Relapse and recurrence

Major depression is a recurrent mental health condition; around 67% of patients have at

least one recurrence every 10 years (Solomon et al., 2000). Patients with residual symptoms were

3 times more likely to relapse than the fully recovered patients (0.76 from partial remission vs.

0.25 from full remission) (Judd et al., 1998). The number of previous episodes and treatment

status affected the probability of recurrences. We obtained base recurrence rates for patients who

had a history of cases pertaining to depression from (Solomon et al., 2000) and patients who had

one previous case and determined that they indicated an increased risk of recurrence by 16%

compared to the base. Patients with 2 or more previous episodes had an additional 32% risk of

recurrence (Solomon et al., 2000).

200   Patients who recovered from major remission without appropriate medication or other

201   treatments were more likely (relative risk of 1.52 to 2.69 (Gelenberg et al., 2003; Lustman et al.,

202   2006; Montgomery et al., 2004; Terra and Montgomery, 1998) for 52 weeks) to relapse. We

203   increased the recurrence rate by 30% for patients transitioning to a remission state from major

204   depression without treatment (Hansen et al., 2008).

206   *Suicide and Death*

207   We assumed that depression-related suicides occur only among major depressive patients

regardless of treatment status. We derived the transition probabilities for suicide from the

modifications noted in (Valenstein et al., 2001) for age and gender-specific rates. The validity of

suicide rates was ensured by comparing the suicide prevalence ratios from 2001 to 2018 (Center

for Suicide Prevention, 2020; National Institute of Mental Health, 2019). We assumed that at

least 50% of suicides were related to depression and 50-80% of older adults who die

by suicide have been shown to have major depression (Center for Suicide Prevention, 2020).

214   Age-specific death from other causes was used (Arias et al., 2017), and we assumed that

215   the major depressive patients had increased their risk of death based on other reasons by a ratio

216   of 1.58 (Cuijpers et al., 2014).

218   *Screening Tools*

219   For the baseline model, the detection rate of depression in usual care settings increased

220   by 50% (Valenstein et al., 2001) for major depression (baseline 45% vs. with screening 68%)

221   and 23% (Valenstein et al., 2001) for minor depression (baseline 30% vs. 37% with screening).

223   *Costs and Utilities*

224   We conducted our analysis from the societal perspective, which took into account direct

and indirect costs (Table 2). We assumed that patients who received treatment from primary care

settings had 4 visits plus a follow-up visit in a year (Valenstein et al., 2001). Patients treated by

mental health specialists had around 11 visits (Valenstein et al., 2001). 31% of patients received

treatment from mental health specialists (26% self-refer and 5% referred by primary care

physician) in a year (Valenstein et al., 2001). Additionally, 1% of patients have inpatient visits in

a 12-month period with an average of 11.6 days of stay. On the other hand, the cost of minor

depression was estimated as two-thirds of major depression (Cuijpers et al., 2007). We calculated

the average treatment cost of partial remission (Israel, 2010) as $1095, based on the number of

remaining symptoms. We assumed there is no direct or indirect cost to capture during full

remission states, as for the healthy state.

The indirect cost was 20% lower in untreated patients ($1600 for treated vs. $3360 for

untreated). The overall cost of major depression with treatment was estimated at $3087 vs. $3360

for major depression without treatment, which was similar to the estimates from (Cuijpers et al.,

2007).

Utility estimates for all health states were obtained from the literature (Table 2). We

assumed that depression with and without treatment states had the same utilities.

Incremental Cost-effectiveness Ratio (ICER)

For all screening scenarii, costs and effects were compared to a situation without

screening. Strategies were evaluated based on the incremental cost-effectiveness ratio (ICER),

which was calculated as the incremental costs per incremental Quality-Adjusted Life Years

(QALY) gained (Equation (1)). The scenario up to the willingness-to-pay (WTP) threshold of

$50 000 per additional QALY gained was classified as optimal (Cohen and Reynolds, 2008).

$$ICER = \frac{\text{Cost}_{Screening} - \text{Cost}_{Baseline}}{\text{QALY}_{Screening} - \text{QALY}_{Baseline}} \qquad (1)$$

Uncertainty Analysis

We performed a one-way sensitivity analysis on critical parameters (Valenstein et al.,

2001). We obtained all the varying values of sensitivity analysis parameters from the literature

(Supplementary Table S1). We used the medium and high values of incidence and prevalence

(Eaton et al., 2007; Kessler et al., 2010) and matched two of these with using recall bias rates

(Yildirim et al., 2021) for sensitivity analysis. Additionally, we tested sensitivity levels for other

parameters such as remission rate from major depression treatment, the utility of major

depression, cost of screening, treatment, and indirect costs.

We also performed Monte Carlo replications to report uncertainties with Bootstrapping-
type analysis. We calculated the average incremental cost and QALY pairs to determine which
proportion of ICER estimates lie below WPT, and 95% confidence intervals (CI) of ICERs.
260
261   **RESULTS**
262
Screening Impact on Outcome Measures
The mean duration in treatment was estimated from the simulation model as 1.26 years
for major depression and 1.32 months for minor depression among females. The suicide rates in
the baseline model were 5.11 for females and 18.08 for males per 100,000 people in a year.
Annual screening could prevent 24.3 cases of suicide per 10,000,000 people in a year (Table 3).
Annual screening also shortened the initiation of the treatment time by 5.3 (vs. 2.8 for 2-year
screening and 1.1 for 5-year screening) months for females and 3.2 (vs. 1.7 for 2-year screening
and 0.6 for 5-year screening) months for males. Annual screening increased the depression-free
months up to 5.5 months per year. All the screening scenarii extended time spent in remission
(11 days to 1.9 months for females and 7 to 29 days for males based on screening schedule).
Table 3 shows that, in the general population, all screening frequencies were cost-
effective compared with the baseline. However, there exists a difference between the male and
female populations based on cost-utility. Females had lower ICERs, and the annual screening
had the highest ratio, with $11,134 cost per QALY gained. On the other hand, males had around
3 times higher ICER, with annual screening $34,072 cost per QALY gained.
278
Uncertainty Analysis
One-way Sensitivity Analysis
In our baseline analysis, we observed that screening was cost-effective for both genders
with low incidence and prevalence (conservative case). Consequently, the screening under
medium and high incidence rates was cost-effective for females and males. For females, lower
ICERs were observed compared to those for males.
Additional analysis on the other parameters such as the remission rate from major
depression treatment, the utility of major depression, cost of screening, treatment, and indirect
costs showed that female ICERs were not sensitive to any changes in these parameters. However,

the ICERs of the male population were higher than $50,000 by using the upper limit of the

screening (Figure 2).

Uncertainty among Monte-Carlo Simulations

Figure S2 (in supplementary) showed every single average incremental cost and QALY

pairs for 1000 replications. For the female population, simulation results showed that all ICERs

were less than the WTP threshold of $50,000. Additionally, less than 10 percent of simulation

runs for males were greater or equal to the WTP threshold in every scenario (Figure S1).

Age-Specific Analysis

Three different age groups, young (18-34), middle (35-64), and old (65+) were analyzed

by evaluating differences in cost-utilities among these subgroups; see Figure S3 (in

Supplementary).

All scenarii were cost-effective for each age group of the female population. For the

oldest population, about 10% of the simulations have ICERs between $50,000 and $75,000

(please see Supplementary Figure S1).

Young and middle age groups of the male population had ICER values up to

$32,090/QALY gained. On average, screening with any frequency was not cost-effective for the

oldest male population.

DISCUSSION

Annual screening of all adults 18 years old or older for depression would be $11,134 and

$34,072 cost per QALY gained for females and males, respectively. In comparison, screening

every 5-years resulted in $8627 cost per QALY gained for females and $26,892 cost per QALY

gained for males. We found that the benefit of early detection and treatment results in the

improvement of QALYs. For both genders, annual screening produced greater costs. The ICER

decreased with increasing screening frequency for males, whereas it rose from 2-year to 5-year

screening in the female population.

In the literature, the combined results from trials showed that depression screening

increased the treatment rates between 2 to 50% (Pignone et al., 2002). In our model, patients

spent an average of 3.65 years to initiate treatment for first-onset major depression. The World

Health Organization's (WHO's) World Mental Health Survey showed that 35% of patients had 4

years of untreated time before initiating the treatment (Wang et al., 2005). We observed that

screening decreased the detection time up to 5 months and increased the remission time up to 1.9
months.

Based on the general intuition, depression treatments could help to improve patient's
mood and depressive symptoms. However, some studies showed that 10% to 30% of patients
experienced adverse outcomes from treatments (e.g., antidepressants) such as functional
impairment, poor quality of life (Al-Harbi, 2012). Therefore, we chose conservative estimates for
utilities. For example, we assumed that the utility of major depression with and without treatment
was the same. Consequently, our results were not biased towards screening.

The age-specific analysis showed that screening of old populations had higher ICERs
than the young and middle age groups. In the old male population, ICERs of all screening
scenarii were below the WTP threshold of $50,000. The main reason for gender differences in
the cost-effectiveness of screening was the varying incidence and prevalence of major
depression. In literature, men had lower incidence rates than women (Eaton et al., 2007),
although there is concern that these rates were not reflecting the truth (Smith et al., 2018). There
were a couple of factors that may cause the underestimation of the rates for males. Firstly, the
measurement bias was observed in data because of the inadequate attendance to surveys and
lower primary care visits (Smith et al., 2018). Secondly, men were less likely than women to
have symptoms of depression that fit standard measurement tools. They experienced more
externalizing symptoms, such as aggression, violence, and substance abuse. Studies showed that
including these alternative symptoms with traditional symptoms as diagnosis criteria had
increased the male prevalence rates to have equal proportions with females (Martin et al., 2013).
We evaluated the alternative incidence, prevalence, and screening scenarii for males with the
same frequency as females. Our results are summarized in the Supplementary file.

We evaluated the external consistency of our model. By running the open network model
for a longer time, where new individuals were introduced into the system at the age of 18 with
the mortality rate, we observed that our initial distribution was equal to steady-state distribution.
This was the case when transient behavior was not observed in the system. To obtain a consistent
system, we adjusted the lifetime prevalence of major depression using reported recall bias rates
(Yildirim et al., 2021).

Interventions (e.g., training primary care physicians to better identify patients with
suicidal thoughts) that have an immediate cost but have gains observed during many years were

less cost-effective under discounting. For interventions like screening, the costs and health

benefits follow the same time pattern so are all affected equally by the discount factor, and the

relative ICER comparisons between policies are unchanged, regardless of the discounting

(Jamison et al., 2006). We ran additional computational results (similar to Table 3) with a

discount factor. In each case, the ICER that we found fell within the 95% confidence interval on

the ICER currently in Table 3. We also find that the relative ICER comparisons between policies

continue to hold, such as the cost-effectiveness of the screening for the general adult population,

2-year screening ICER is less (more) than 5-year screening ICER for females (males). Therefore,

we did not include the discount rate of utilities and costs in the body of the paper.

This paper evaluated the general U.S. population during the non-crises period (e.g.,

economic problems, or pandemics). Recent studies showed that during COVID-19, incidence

and prevalence were reported three times higher for moderate and severe depression (Ettman et

al., 2020). We further included the prevalence rate changes between 2020 and 2021 in our

analysis. Our results indicated that the depression screening is cost-saving for females at 2 and 5-

year screening frequencies and around $11,000 to $15,000 ICERs for males based on the

screening interval between 2020 to 2040 (please see Supplementary file).

LIMITATIONS

The cost-effectiveness of screening may be enhanced by targeting groups with a higher

incidence of depression based on ethnicity, comorbidities, or poverty level. However, we

analyzed screening scenarii that are valid for the general adult population. Because of incidence,

disease progression, and suicide rate difference between females and males, we only considered

the gender-specific model. We also extended our analysis for different age groups.

Our model did not consider the differences among the screening tools; we used average

test sensitivity for 9 standard screening instruments. We assumed that the screening frequency

was not changing at any time during the screening scenario. In our calculations, false-positive

cases were not taken into account.

We did not consider the severity of major depression; however, we included the details

about elevated risk based on age, gender, history of depression (major or minor), number of

previous episodes, remaining symptoms for onset depression, treatment status, type of treatment

and time spent without treatment states. We did not exclusively include medication drop-out

rates (transition from treatment to without treatment) in our analysis. However, the treatment
rates obtained from the literature implicitly include the response of adherent and non-adherent
patients who are not fully complied the clinical treatment guidelines.

Like Valenstein's model, (Valenstein et al., 2001) we assumed that suicide might happen
when the patient had active major depression. Patients did not have direct and indirect costs (e.g.,
productivity loss) when they were in full remission; however, staying there for a long time
decrease the risk of relapses. But distinct from their work, we used more detailed remission
states, e.g., partial and full remission from different types of depression. We did not consider the
medication costs that arose when patients were in remission. In the annual transition model,
patients spent at least one year in treatment when they transition to treatment states, which is
more than suggested acute therapy (6-12 weeks) and continuation therapy (4-8 months). We
assumed that patients in partial remission with residual symptoms had received maintenance
treatment.

CONCLUSIONS

Depression is a common health condition that affects an individual's everyday life.
Considering the high lifetime prevalence and recurrence rates of depression, detection and
prevention efforts play an essential role. Furthermore, the increasing trend in suicide rates
becomes an emerging public health problem. We conclude that routine screening is cost-
effective for all age groups of females and young and middle-aged males. Male population
results are sensitive to the higher costs of screening, which indicates that if the screening cost is
44% higher than the average cost, the screening of the male population is not cost-effective. Our
analysis combines the expected benefits and costs of screening and assesses the effectiveness of
screening scenarii. Screening can be one of the cornerstones to support required care. Our
baseline model could be used to evaluate the potential consequences of medication strategies or
alternative   intervention   scenarii.

Acknowledgements: The authors are grateful to the Editors and anonymous reviewers for their thoughtful, constructive comments.

REFERENCES

Al-Harbi, K.S., 2012. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 6, 369-388.

Arias, E., Heron, M., Xu, J., 2017. United States Life Tables, 2014. Natl Vital Stat Rep 66, 1-64. Bukh, J.D., Bock, C., Vinberg, M., Kessing, L.V., 2013. The effect of prolonged duration of untreated depression on antidepressant treatment outcome. J Affect Disord 145, 42-48.

Center for Disease Control and Prevention, 2020. Facts about suicide. October 22, 2021, https://www.cdc.gov/suicide/facts/index.html.

Center for Suicide Prevention, 2020. Depression and Suicide Prevention. February 20, 2020, https://www.suicideinfo.ca/resource/depression-suicide-prevention/.

Cohen, D.J., Reynolds, M.R., 2008. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 52, 2119-2126.

Cuijpers, P., Smit, F., Oostenbrink, J., de Graaf, R., Ten Have, M., Beekman, A., 2007. Economic costs of minor depression: a population-based study. Acta Psychiatr Scand 115, 229-236.

Cuijpers, P., Vogelzangs, N., Twisk, J., Kleiboer, A., Li, J., Penninx, B.W., 2014. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. Am J Psychiatry 171, 453-462.

Eaton, W.W., Anthony, J.C., Gallo, J., Cai, G., Tien, A., Romanoski, A., Lyketsos, C., Chen, L.S., 1997. Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The Baltimore Epidemiologic Catchment Area follow-up. Arch Gen Psychiatry 54, 993-999.

Eaton, W.W., Kalaydjian, A., Scharfstein, D.O., Mezuk, B., Ding, Y., 2007. Prevalence and incidence of depressive disorder: the Baltimore ECA follow-up, 1981-2004. Acta Psychiatr Scand 116, 182-188.

Ettman, C.K., Abdalla, S.M., Cohen, G.H., Sampson, L., Vivier, P.M., Galea, S., 2020. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Netw Open 3, e2019686-e2019686.

Fils, J.M., Penick, E.C., Nickel, E.J., Othmer, E., Desouza, C., Gabrielli, W.F., Hunter, E.E., 2010. Minor versus major depression: a comparative clinical study. Prim Care Companion J Clin Psychiatry 12, PCC 08m00752.

Gelenberg, A.J., Trivedi, M.H., Rush, A.J., Thase, M.E., Howland, R., Klein, D.N., Kornstein, S.G., Dunner, D.L., Markowitz, J.C., Hirschfeld, R.M., Keitner, G.I., Zajecka, J., Kocsis, J.H., Russell, J.M., Miller, I., Manber, R., Arnow, B., Rothbaum, B., Munsaka, M., Banks, P., Borian, F.E., Keller,

M.B., 2003. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry 54, 806-817.

Goodwin, G.M., 2006. Depression and associated physical diseases and symptoms. Dialogues Clin Neurosci 8, 259-265.

Greenberg, P.E., Fournier, A.A., Sisitsky, T., Pike, C.T., Kessler, R.C., 2015. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 76, 155-162.

Hansen, R., Gaynes, B., Thieda, P., Gartlehner, G., Deveaugh-Geiss, A., Krebs, E., Lohr, K., 2008. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 59, 1121-1130.

Howden, B., Meyer, J.A., 2010. Age and Sex Composition: 2010. October 27, 2021, https://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf.

Israel, J.A., 2010. The Impact of Residual Symptoms in Major Depression. Pharmaceuticals (Basel) 3, 2426-2440.

Jamison, D.T., Breman, J.G., Measham, A.R., Alleyne, G., Claeson, M., Evans, D.B., Jha, P., Mills, A., Musgrove, P., 2006. Priorities in Health.

Judd, L.L., Akiskal, H.S., Maser, J.D., Zeller, P.J., Endicott, J., Coryell, W., Paulus, M.P., Kunovac, J.L., Leon, A.C., Mueller, T.I., Rice, J.A., Keller, M.B., 1998. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50, 97-108.

Kessler, R.C., Birnbaum, H., Bromet, E., Hwang, I., Sampson, N., Shahly, V., 2010. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychol Med 40, 225-237.

Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C.A., Jr., Kasper, S., 2019. Prognosis and improved outcomes in major depression: a review. Transl Psychiatry 9, 127.

Lustman, P.J., Clouse, R.E., Nix, B.D., Freedland, K.E., Rubin, E.H., McGill, J.B., Williams, M.M., Gelenberg, A.J., Ciechanowski, P.S., Hirsch, I.B., 2006. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 63, 521-529.

Mark T. Linthicum, M.P.P., Yuri Sanchez Gonzalez, P., Karen Mulligan, P., Gigi A. Moreno, P., David Dreyfus, D.B.A., Timothy Juday, P., Steven E. Marx, P., Darius N. Lakdawalla, P., Brian R. Edlin, M.D., Ron Brookmeyer, P., 2016. Value of Expanding HCV Screening and Treatment Policies in the United States. The American Journal of Managed Care 22.

Martin, L.A., Neighbors, H.W., Griffith, D.M., 2013. The experience of symptoms of depression in men vs women: analysis of the National Comorbidity Survey Replication. JAMA Psychiatry 70, 1100-1106.

Montgomery, S.A., Entsuah, R., Hackett, D., Kunz, N.R., Rudolph, R.L., Venlafaxine 335 Study, G., 2004. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 65, 328-336.

National Center for Health Statistics, 2018. NAMCS and NHAMCS Web Tables. October 27, 2021, https://www.cdc.gov/nchs/ahcd/web_tables.htm.

National Institute for Health and Clinical Excellence: Guidance, 2010. Depression: The Treatment and Management of Depression in Adults (Updated Edition). October 27, 2021, https://www.ncbi.nlm.nih.gov/pubmed/22132433.

National Institute of Mental Health, 2019. Suicide. February 24, 2020, https://www.nimh.nih.gov/health/statistics/suicide.shtml.

O'Connor, E., Rossom, R.C., Henninger, M., Groom, H.C., Burda, B.U., Henderson, J.T., Bigler, K.D., Whitlock, E.P., 2016. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Screening for Depression in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force.

Pignone, M.P., Gaynes, B.N., Rushton, J.L., Burchell, C.M., Orleans, C.T., Mulrow, C.D., Lohr, K.N., 2002. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136, 765-776.

Ross, E.L., Vijan, S., Miller, E.M., Valenstein, M., Zivin, K., 2019. The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model. Ann Intern Med 171, 785-795.

Sleath, B.L., Thomas, N., Jackson, E., West, S.L., Gaynes, B.N., 2007. Physician reported communication about depression and psychosocial issues during postpartum visits. N C Med J 68, 151-155.

Smith, D.T., Mouzon, D.M., Elliott, M., 2018. Reviewing the Assumptions About Men's Mental Health: An Exploration of the Gender Binary. American journal of men's health 12, 78-89. Solomon, D.A., Keller, M.B., Leon, A.C., Mueller, T.I., Lavori, P.W., Shea, M.T., Coryell, W., Warshaw, M., Turvey, C., Maser, J.D., Endicott, J., 2000. Multiple recurrences of major depressive disorder. Am J Psychiatry 157, 229-233.

Takayanagi, Y., Spira, A.P., Roth, K.B., Gallo, J.J., Eaton, W.W., Mojtabai, R., 2014. Accuracy of reports of lifetime mental and physical disorders: results from the Baltimore Epidemiological Catchment Area study. JAMA Psychiatry 71, 273-280.

Terra, J.L., Montgomery, S.A., 1998. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 13, 55-62.

Thombs, B.D., Coyne, J.C., Cuijpers, P., de Jonge, P., Gilbody, S., Ioannidis, J.P.A., Johnson, B.T., Patten, S.B., Turner, E.H., Ziegelstein, R.C., 2012. Rethinking recommendations for screening for depression in primary care. CMAJ 184, 413-418.

U.S. Preventive Services Task Force, 2016. Depression in Adults: Screening. October 27, 2021, https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/depression-in-adults-screening.

Valenstein, M., Vijan, S., Zeber, J.E., Boehm, K., Buttar, A., 2001. The cost-utility of screening for depression in primary care. Ann Intern Med 134, 345-360.

Wang, P.S., Berglund, P., Olfson, M., Pincus, H.A., Wells, K.B., Kessler, R.C., 2005. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62, 603-613.

Yildirim, M., Gaynes, B.N., Keskinocak, P., Pence, B.W., Swann, J., 2021. DIP: Natural history model for major depression with incidence and prevalence. J Affect Disord 296, 498-505.

Figure 1. Markov Health State Model

Table 1. *Major and minor depression parameters*

Major Depression					
Definition	**Probability**	**Age Group**	**Gender-specific**	**Related States or Transitions**	**Reference**
Point Prevalence %					
Major depression without treatment: -18-34[a] -35-49[b] -50-64[c] -65+[d]	Female: 10.72[a], 8.91[b], 7.17[c], 2.92[d] Male: 5.08[a], 5.22[b], 4.3[c], 0.85[d]	Yes	Yes	25	Calculated (Kessler et al., 2010), (Yildirim et al., 2021)
Major depression with treatment: -18-34[a] -35-49[b] -50-64[c] -65+[d]	Female: 6.28[a], 5.22[b], 4.2[c], 1.71[d] Male: 2.77[a], 2.85[b], 2.35[c], 0.46[d]	Yes	Yes	25	Calculated (Kessler et al., 2010), (Yildirim et al., 2021)
Partial remission	3	No	No	25	Assumed
Full remission: -18-34[a] -35-49[b] -50-64[c] -65+[d]	Female: 9.09[a], 19.14[b], 20.59[c], 24.71[d] Male: 7.93[a], 11.71[b], 11.56[c], 14.76[d]	Yes	Yes	25	Calculated (Kessler et al., 2010), (Yildirim et al., 2021)
Death from other causes	Female: 0.16, Male: 0.17	No	Yes	25	(Arias et al., 2017)
Suicide	Female: 0.000486, Male: 0.00189	No	Yes	25	(National Institute of Mental Health, 2019)
Incidence					
Major depression among never depressed patients: -18-29[a] -30-44[b] -45-64[c] -65+[d]	Female: 0.0019[a], 0.0045[b] 0.0011[c], 0.0002[d] Male: 0.0002[a], 0.002[b], 0.0001[c], 0.00004[d]	Yes	Yes	2	(Eaton et al., 2007)
Major depression in patients with minor depression	0.127	No	No	4	(Tuithof et al., 2018) (Frank et al., 2002) (Hermens et al., 2004) (Broadhead et al., 1990)
Recurrence					
Recurrence of major depression (History = 1 previous episodes): -18-24[a] -25-34[b] -35-44[c] -45+[d]	Female: 0.29[a], 0.24[b], 0.29[c], 0.26[d] Male: 0.35[a], 0.22[b], 0.23[c], 0.08[d]	Yes	Yes	23	Calculated from (Kessler et al., 1994) and (Solomon et al., 2000)

Definition	Probability	Age Group	Gender-specific	Related States or Transitions	Reference
- History = 2 previous episodes	Increased 0.16	No	No		(Solomon et al., 2000)
- History >= 3 previous episodes	Increased 0.32	No	No		(Solomon et al., 2000)
- From without treatment state risk multiplier	1.3	No	No		(Hansen et al., 2008)
Relapse from partial remission	0.76		No	19	(Paykel, 2008)
Recovery from partial remission	0.22	No	No	21	(Brodaty et al., 1993)
Recurrence from minor remission	0.055	No	No	9	Assumed
Treatment					
Initiation of treatment: -18-34[a] -35-49[b] -50-64[c] -65+[d]	0.451[a], 0.602[b], 0.5071[c], 0.433[d]	Yes	No	12	Calculated (Kessler et al., 2010), (Valenstein et al., 2001)
Detection of disease	Without screening 0.45, with screening 0.68	No	No	12	(Valenstein et al., 2001)
Without care full remission	0.37	No	No	13	(Whiteford et al., 2013)
Without care partial remission	0.1	No	No	11	(Goldberg et al., 1998)
In usual care full remission	0.503	No	No	16	(Judd et al., 1998)
Duration of untreated illness (DUI) >= 12 mo. (to reach full remission) risk multiplier	1.3	No	No		(Bukh et al., 2013)
In usual care partial remission: -18-39[a] -40-59[b] -60+[c]	0.21[a], 0.29[b], 0.24[c]	Yes	No	18	(Judd et al., 1998), (Brodaty et al., 1993)
Mortality					
Mortality rate for general population	Refer for full list	20 to 100	Yes	24	(Arias et al., 2017)
Mortality risk multiplier	1.58	No	No		(Cuijpers et al., 2014)
Suicide: -18-34[a] -35-54[b] -55-64[c] -65+[d]	Female: 0.0001375[a], 0.0001[b], 0.000575[c], 0.0032[d] Male: 0.0003875[a], 0.00204[b], 0.0022[c], 0.0038[d]	Yes	Yes	14, 17	(National Institute of Mental Health, 2019; Valenstein et al., 2001)
Minor Depression					
Definition	**Probability**	**Age Group**	**Gender-specific**	**Related States or Transitions**	**Reference**

Point Prevalence (%)					
Minor depression	5.86	No	No	25	(Rodriguez et al., 2012)
Depression without treatment	5.494	No	No	25	(Kessler et al., 1997)
Minor depression with treatment	0.366	No	No	25	(Kessler et al., 1997)
Full remission	13	No	No	25	(Kessler et al., 1997)
Incidence					
Minor depression among never depressed patients	0.0087	No	No	1	(Tuithof et al., 2018)
Minor depression among major depressive patients	0.040	No	No	10	(Forsell, 2007)
Minor depression among partial remission	0.019	No	No	20	(Forsell, 2007)
Minor depression among full remission from major depression patients	0.03	No	No	22	Assumed
Recurrence					
Recurrence of Minor depression	0.16	No	No	8	(Broadhead et al., 1990) (Hermens et al., 2004)
Treatment					
Initiation of treatment	0.2	No	No	3	(Valenstein et al., 2001)
Detection of disease	Without screening: 0.3, with screening: 0.37	No	No	3	(Valenstein et al., 2001)
Without care full remission	0.55	No	No	5	(Frank et al., 2002)
In usual care full remission	0.714	No	No	7	(Hermens et al., 2004), (Broadhead et al., 1990), (Alexopoulos et al., 2009), (Frank et al., 2002), (Ceroni et al., 2002)

Table 2. *Cost and utilities for each health state.*

COSTS			
Variable	**Description**	**Point Estimate ($)**	**Reference**
Initial visit to primary care physician		45.85	(Valenstein et al., 2001)
Administration of screening cost		4.88	(Valenstein et al., 2001)
Screening cost		50.73	(Valenstein et al., 2001)
Treatment of depression in primary care settings	4 visits and follow-up visits in a year	398.72	(Valenstein et al., 2001)
Treatment of depression by mental health specialist	11 visit/year	1020.14	(Valenstein et al., 2001)
Medication cost (outpatient)		677.16	(Valenstein et al., 2001)
Hospitalization cost	Average length of stay 11.61 days	11610	(Valenstein et al., 2001)
Physician professional fees (hospital)	Daily inpatient physician visits (based on average length of stay)	878.99	(Valenstein et al., 2001)
Medication in hospital	Based on average length of stay	21.83	(Valenstein et al., 2001)
Indirect cost of major depression	Extrapolated from lost workdays of treated and untreated patients with major depression 1 year	1600 for patients receiving treatment; 3360 for patients not receiving treatment	(Valenstein et al., 2001)
Minor depression with treatment	2/3 of major depression cost	2141	(Cuijpers et al., 2007)
Minor depression without treatment	Indirect cost	2101	(Cuijpers et al., 2007)
Partial remission	on average 2-3 symptoms	1095	(Cuijpers et al., 2007), (Israel, 2010)
UTILITIES			
State	**Description**	**Utilities**	**Reference**
Major depression	Same for with and without treatment	0.63	(Valenstein et al., 2001)

Minor depression, partial remission	Same for with and without treatment	0.7	(Valenstein et al., 2001)
Full remission	Same for full remission from minor and major depression	0.89	(Valenstein et al., 2001)

Table 3. Cost-effectiveness measures of screening scenarios (average of 1000 replications)

Scenario	Costs,$	QALYs	ICER Cost/QALY gained, $ compared to Baseline (95% CI)*	Average Annual Depression-related Suicides (/100,000)	Total Depressive Time (yr)	Minor Depression without Treatment Time (yr)	Minor Depression with Treatment Time (yr)	Major depression without Treatment Time (yr)	Major depression with Treatment Time (yr)	Total Remission Time (Full, Partial, Minor or Major) (yr)
FEMALE										
Baseline	$14,317	18.265	Reference	5.107	7.23	2.61	0.11	3.26	1.26	6.84
5-year	$14,391	18.274	$8627 ($1428 – $13,151)	5.086	7.13	2.54	0.11	3.17	1.31	6.87
2-year	$14,503	18.287	$8600 ($3750 – $14,705)	5.065	7.01	2.50	0.12	3.03	1.36	6.93
Annual	$14,751	18.304	$11,134 ($7872 – $25,500)	5.036	6.77	2.43	0.13	2.82	1.40	7.00
MALE										
Baseline	$8864	18.963	Reference	18.078	5.95	2.93	0.14	2.05	0.84	5.72
5-year	$9002	18.969	$26,913 ($11,321 – $41,375)	18.036	5.86	2.84	0.14	2.00	0.88	5.74
2-year	$9213	18.975	$29,768 ($18,647 – $43,458)	18.026	5.78	2.83	0.15	1.91	0.88	5.76
Annual	$9587	18.985	$34,072 ($27,185 – $49,669)	17.906	5.60	2.74	0.17	1.78	0.92	5.80

CI: Confidence interval

ICER: Incremental cost-effectiveness ratio

SE: Standard error

*95% confidence interval calculated based on bootstrapping method